

PhI Spuls

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5284209/publications.pdf>

Version: 2024-02-01

204
papers

11,850
citations

39113

52
h-index

36203

101
g-index

211
all docs

211
docs citations

211
times ranked

10681
citing authors

#	ARTICLE	IF	CITATIONS
1	On which evidence can we rely when prescribing off-label methotrexate in dermatological practice? â€“ a systematic review with GRADE approach. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1947-1966.	1.1	2
2	Can serum biomarkers predict the outcome of systemic immunosuppressive therapy in adult atopic dermatitis patients?. <i>Skin Health and Disease</i> , 2022, 2, e77.	0.7	4
3	Barriers and facilitators for systematically registering adverse drug reactions in electronic health records: a qualitative study with Dutch healthcare professionals. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 699-706.	1.0	5
4	Vaccine hesitancy and access to psoriasis care during the <scp>COVID</scp> â€“19 pandemic: findings from a global patientâ€“reported crossâ€“sectional survey. <i>British Journal of Dermatology</i> , 2022, 187, 254-256.	1.4	11
5	Classifying atopic dermatitis: a systematic review of phenotypes and associated characteristics. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 807-819.	1.3	14
6	Neurological signs, symptoms and MRI abnormalities in patients with congenital melanocytic naevi and evaluation of routine MRI-screening: systematic review and meta-analysis. <i>Orphanet Journal of Rare Diseases</i> , 2022, 17, 95.	1.2	9
7	Adalimumab with Methotrexate vs. Adalimumab Monotherapy in Psoriasis: First-Year Results of a Single-Blind Randomizedâ€“Controlled Trial. <i>Journal of Investigative Dermatology</i> , 2022, 142, 2375-2383.e6.	0.3	19
8	International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis. <i>JAMA Dermatology</i> , 2022, 158, 561.	2.0	12
9	Risk factors associated with short-term adverse events after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases. <i>BMC Medicine</i> , 2022, 20, 100.	2.3	15
10	From the Cochrane Library: Phototherapy for atopic eczema. <i>Journal of the American Academy of Dermatology</i> , 2022, , .	0.6	0
11	The HOME Core outcome set for clinical trials of atopic dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 1899-1911.	1.5	51
12	Systemic Immunomodulatory Treatments for Atopic Dermatitis. <i>JAMA Dermatology</i> , 2022, 158, 523.	2.0	70
13	Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study. <i>Lancet Rheumatology</i> , The, 2022, 4, e338-e350.	2.2	88
14	Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies. <i>Lancet Rheumatology</i> , The, 2022, 4, e417-e429.	2.2	33
15	Immunogenicity of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Followed by the 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) in Adults with and without Immunosuppressive Therapy. <i>Vaccines</i> , 2022, 10, 795.	2.1	6
16	A core outcome domain set for clinical research on capillary malformations (the COSCAM project): an e-Delphi process and consensus meeting. <i>British Journal of Dermatology</i> , 2022, 187, 730-742.	1.4	3
17	Outcome assessment in dermatology clinical trials and cochrane reviews: call for a dermatologyâ€“specific outcome taxonomy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 523-535.	1.3	15
18	Immunogenicity of biologic therapies in psoriasis: Myths, facts and a suggested approach. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 329-337.	1.3	13

#	ARTICLE	IF	CITATIONS
19	Factors associated with adverse COVID-19 outcomes in patients with psoriasisâ€”insights from a global registryâ€”based study. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 60-71.	1.5	136
20	Development of an international core domain set for medium, large and giant congenital melanocytic naevi as a first step towards a core outcome set for clinical practice and research*. <i>British Journal of Dermatology</i> , 2021, 185, 371-379.	1.4	9
21	The Selection Process for a Web-Based Application to Measure Patient-Reported Outcomes Following the Example of the TREAT NL Registry. <i>Journal of Investigative Dermatology</i> , 2021, 141, 1592-1595.e1.	0.3	1
22	EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris â€” Part 2: specific clinical and comorbid situations. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 281-317.	1.3	84
23	Recommended core outcome instruments for healthâ€”related quality of life, longâ€”term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting*. <i>British Journal of Dermatology</i> , 2021, 185, 139-146.	1.4	52
24	Responsiveness of quality of life measures in children with peripheral vascular malformations: The OVAMA project. <i>JPRAS Open</i> , 2021, 27, 70-79.	0.4	8
25	European Task Force on Atopic Dermatitis: position on vaccination of adult patients with atopic dermatitis against COVIDâ€”19 (SARSâ€”CoVâ€”2) being treated with systemic medication and biologics. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e308-e311.	1.3	27
26	Riskâ€”mitigating behaviours in people with inflammatory skin and joint disease during the COVIDâ€”19 pandemic differ by treatment type: a crossâ€”sectional patient survey*. <i>British Journal of Dermatology</i> , 2021, 185, 80-90.	1.4	26
27	Online decision aid for patients with psoriasis. <i>British Journal of Dermatology</i> , 2021, 184, 981-983.	1.4	1
28	Surgical Treatment of Peripheral Vascular Malformations: A Systematic Review and Meta-Analysis. <i>Plastic and Reconstructive Surgery</i> , 2021, 147, 1149-1161.	0.7	10
29	Risk of severe allergic reactions to COVIDâ€”19 vaccines among patients with allergic skin diseases â€” practical recommendations. A position statement of ETFAD with external experts. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e362-e365.	1.3	24
30	POS0271-HPRâ€”...PATIENT PERSPECTIVE ON A DRUG SAFETY MONITORING SYSTEM FOR IMMUNE-MEDIATED INFLAMMATORY DISEASES BASED ON PATIENT-REPORTED OUTCOMES. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 359.2-359.	0.5	0
31	Gastrointestinal Adverse Drug Reaction Profile of Etanercept: Real-world Data From Patients and Healthcare Professionals. <i>Journal of Rheumatology</i> , 2021, 48, 1388-1394.	1.0	2
32	Work ability and quality of working life in atopic dermatitis patients treated with dupilumab. <i>Journal of Dermatology</i> , 2021, 48, 1305-1314.	0.6	5
33	Do patient characteristics matter when calculating sample size for eczema clinical trials?. <i>Skin Health and Disease</i> , 2021, 1, e42.	0.7	3
34	Learning from disease registries during a pandemic: Moving toward an international federation of patient registries. <i>Clinics in Dermatology</i> , 2021, 39, 467-478.	0.8	9
35	Development of a conditionâ€”specific patientâ€”reported outcome measure for measuring symptoms and appearance in vascular malformations: the OVAMA questionnaire. <i>British Journal of Dermatology</i> , 2021, 185, 797-803.	1.4	13
36	Paternal and maternal use of dupilumab in patients with atopic dermatitis: a case series. <i>Clinical and Experimental Dermatology</i> , 2021, 46, 1089-1092.	0.6	14

#	ARTICLE	IF	CITATIONS
37	Development of a core outcome domain set for clinical research on capillary malformations (the Tj ETQq1 1 0.784314 rgBT /Overlock 1888-1895.	1.3	2
38	Domains and outcomes of the core outcome set of congenital melanocytic naevi for clinical practice and research (the OCOMEN project): part 2*. British Journal of Dermatology, 2021, 185, 970-977.	1.4	7
39	Describing the burden of the COVID-19 pandemic in people with psoriasis: findings from a global cross-sectional study. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e636-e640.	1.3	18
40	The BIOMarkers in Atopic Dermatitis and Psoriasis (BIOMAP) glossary: developing a lingua franca to facilitate data harmonization and cross-cohort analyses. British Journal of Dermatology, 2021, 185, 1066-1069.	1.4	10
41	Patients' perspectives on a drug safety monitoring system for immune-mediated inflammatory diseases based on patient-reported outcomes. Expert Opinion on Drug Safety, 2021, 20, 1-8.	1.0	0
42	Response to: "Comment on "Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREATment of ATopic eczema, the Netherlands) registry". Journal of the American Academy of Dermatology, 2021, 85, e173-e174.	0.6	0
43	Clinical characteristics associated with pain in patients with peripheral Vascular Malformations. Journal of Vascular Surgery, 2021, , .	0.6	6
44	Dermatology COVID-19 Registries. Dermatologic Clinics, 2021, 39, 575-585.	1.0	12
45	Phototherapy for atopic eczema. The Cochrane Library, 2021, 2021, CD013870.	1.5	9
46	Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. JAMA Network Open, 2021, 4, e2129639.	2.8	86
47	Effectiveness of dupilumab treatment in 95 patients with atopic dermatitis: daily practice data. British Journal of Dermatology, 2020, 182, 418-426.	1.4	65
48	Outcome measurement instruments for peripheral vascular malformations and an assessment of the measurement properties: a systematic review. Quality of Life Research, 2020, 29, 1-17.	1.5	15
49	Protocol for the development of core set of domains of the core outcome set for patients with congenital melanocytic naevi (OCOMEN project). Journal of the European Academy of Dermatology and Venereology, 2020, 34, 267-273.	1.3	11
50	TREATment of ATopic eczema (TREAT) Registry Taskforce: protocol for a European safety study of dupilumab and other systemic therapies in patients with atopic eczema. British Journal of Dermatology, 2020, 182, 1423-1429.	1.4	14
51	The role of bacterial skin infections in atopic dermatitis: expert statement and review from the International Eczema Council Skin Infection Group. British Journal of Dermatology, 2020, 182, 1331-1342.	1.4	102
52	Responsiveness of quality-of-life measures in patients with peripheral vascular malformations: the OVAMA project. British Journal of Dermatology, 2020, 182, 1395-1403.	1.4	14
53	Effect of immunosuppressive treatment on biomarkers in adult atopic dermatitis patients. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1545-1554.	1.3	15
54	Development and initial testing of a new instrument to measure the experience of eczema control in adults and children: Recap of atopic eczema (<sc>RECAP</sc>). British Journal of Dermatology, 2020, 183, 524-536.	1.4	52

#	ARTICLE	IF	CITATIONS
55	Outcomes and measurement instruments used in congenital melanocytic naevi research: A systematic review. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2020, 73, 703-715.	0.5	6
56	Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting. <i>British Journal of Dermatology</i> , 2020, 185, 139.	1.4	7
57	Patient-Reported Burden of Adverse Drug Reactions Attributed to Biologics Used for Immune-Mediated Inflammatory Diseases. <i>Drug Safety</i> , 2020, 43, 917-925.	1.4	20
58	Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREATment of ATopic eczema, the Netherlands) registry. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1375-1384.	0.6	34
59	Immune-mediated inflammatory disease patients' preferences in adverse drug reaction information regarding biologics. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1049-1054.	1.0	6
60	International collaboration and rapid harmonization across dermatologic COVID-19 registries. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, e261-e266.	0.6	13
61	European Task Force on Atopic Dermatitis statement on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and atopic dermatitis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e241-e242.	1.3	99
62	The current extent of and need for shared decision making in atopic dermatitis and psoriasis in the Netherlands: an online survey study amongst patients and physicians. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2574-2583.	1.3	16
63	Generic outcome set for the international registry on Laser treatments in Dermatology (LEAD): a protocol for a Delphi study to achieve consensus on what to measure. <i>BMJ Open</i> , 2020, 10, e038145.	0.8	3
64	The European TREATment of ATopic eczema (TREAT) Registry Taskforce survey: prescribing practices in Europe for phototherapy and systemic therapy in adult patients with moderate-to-severe atopic eczema*. <i>British Journal of Dermatology</i> , 2020, 183, 1073-1082.	1.4	25
65	Measuring atopic eczema symptoms in clinical practice: The first consensus statement from the Harmonising Outcome Measures for Eczema in clinical practice initiative. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 1181-1186.	0.6	29
66	Global reporting of cases of COVID-19 in psoriasis and atopic dermatitis: an opportunity to inform care during a pandemic. <i>British Journal of Dermatology</i> , 2020, 183, 404-406.	1.4	18
67	Systemic Immunomodulatory Treatments for Patients With Atopic Dermatitis. <i>JAMA Dermatology</i> , 2020, 156, 659.	2.0	104
68	EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 1: treatment and monitoring recommendations. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2461-2498.	1.3	149
69	Towards More Shared Decision Making in Dermatology: Development of Evidence-based Decision Cards for Psoriasis and Atopic Eczema Treatments. <i>Acta Dermato-Venereologica</i> , 2020, 100, adv00337.	0.6	7
70	TREATment of ATopic eczema (TREAT) Registry Taskforce: an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema phototherapy and systemic therapy registries. <i>British Journal of Dermatology</i> , 2019, 180, 790-801.	1.4	26
71	TREATment of ATopic eczema (TREAT) Registry Taskforce: consensus on how and when to measure the core dataset for atopic eczema treatment research registries. <i>British Journal of Dermatology</i> , 2019, 181, 492-504.	1.4	29
72	Navigating the landscape of core outcome set development in dermatology. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 297-305.	0.6	46

#	ARTICLE	IF	CITATIONS
73	European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 1644-1659.	1.3	85
74	Finalizing the international core domain set for peripheral vascular malformations: the <scp>OVAMA</scp> project. <i>British Journal of Dermatology</i> , 2019, 181, 1076-1078.	1.4	11
75	Cochrane Reviews and Dermatological Trials Outcome Concordance: Why Core Outcome Sets Could Make Trial Results More Usable. <i>Journal of Investigative Dermatology</i> , 2019, 139, 1045-1053.	0.3	29
76	Clinical Consequences of Antibody Formation, Serum Concentrations, and HLA-Cw6 Status in Psoriasis Patients on Ustekinumab. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 634-639.	1.0	8
77	Highlights of the updated Dutch evidenceâ€•and consensusâ€•based guideline on psoriasis 2017. <i>British Journal of Dermatology</i> , 2019, 180, 31-42.	1.4	21
78	Reversibility of alexithymia with effective treatment of moderateâ€•toâ€•severe psoriasis: longitudinal data from <scp>EPIDEPSO</scp>. <i>British Journal of Dermatology</i> , 2019, 180, 397-403.	1.4	16
79	Core outcome sets in dermatology: report from the second meeting of the International Cochrane Skin Group Core Outcome Set Initiative. <i>British Journal of Dermatology</i> , 2018, 178, e279-e285.	1.4	29
80	Report from the fifth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative). <i>British Journal of Dermatology</i> , 2018, 178, e332-e341.	1.4	96
81	Core outcome sets in dermatology: report from the second meeting of the International Cochrane Skin Group Core Outcome Set Initiative. <i>British Journal of Dermatology</i> , 2018, 178, e297-e297.	1.4	18
82	By using a core outcome set we measure what matters to patients. <i>British Journal of Dermatology</i> , 2018, 178, 579-580.	1.4	3
83	Reporting of outcomes in randomized controlled trials on nail psoriasis: a systematic review. <i>British Journal of Dermatology</i> , 2018, 178, 640-649.	1.4	12
84	Methotrexate versus azathioprine in patients with atopic dermatitis: 2-year follow-up data. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 825-827.e10.	1.5	19
85	Development of an international core outcome set for peripheral vascular malformations: the OVAMA project. <i>British Journal of Dermatology</i> , 2018, 178, 473-481.	1.4	44
86	Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement. <i>British Journal of Dermatology</i> , 2018, 178, 768-775.	1.4	127
87	Biologics combined with conventional systemic agents or phototherapy for the treatment of psoriasis: realâ€•life data from PSONET registries. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 245-253.	1.3	29
88	Methotrexate and azathioprine for severe atopic dermatitis: a 5-year follow-up study of a randomized controlled trial. <i>British Journal of Dermatology</i> , 2018, 178, 1288-1296.	1.4	40
89	Systemic immunomodulatory treatments for atopic dermatitis: protocol for a systematic review with network meta-analysis. <i>BMJ Open</i> , 2018, 8, e023061.	0.8	12
90	Relationship and probabilistic stratification of Eczema Area and Severity Index and objective Scoring Atopic Dermatitis severity scores for atopic dermatitis. <i>British Journal of Dermatology</i> , 2018, 179, 1003-1005.	1.4	3

#	ARTICLE	IF	CITATIONS
91	Initial Results of Secukinumab Drug Survival in Patients with Psoriasis: A Multicentre Daily Practice Cohort Study. <i>Acta Dermato-Venereologica</i> , 2018, 98, 648-654.	0.6	50
92	Standardized reporting of the Eczema Area and Severity Index (EASI) and the Patient-Oriented Eczema Measure (POEM): a recommendation by the Harmonising Outcome Measures for Eczema (HOME) Initiative. <i>British Journal of Dermatology</i> , 2018, 179, 540-541.	1.4	25
93	Evaluation of the measurement properties of symptom measurement instruments for atopic eczema: a systematic review. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2017, 72, 146-163.	2.7	71
94	Patient-Oriented Eczema Measure (POEM), a core instrument to measure symptoms in clinical trials: a Harmonising Outcome Measures for Eczema (HOME) statement. <i>British Journal of Dermatology</i> , 2017, 176, 979-984.	1.4	141
95	Procollagen α 1(I)N1-terminal peptide measurements for the detection of liver fibrosis in methotrexate-treated patients with psoriasis: daily practice use and clinical implications. <i>British Journal of Dermatology</i> , 2017, 177, 1454-1457.	1.4	6
96	TREatment of ATopic eczema (TREAT) Registry Taskforce: protocol for an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema registries. <i>Trials</i> , 2017, 18, 87.	0.7	21
97	Optimizing adalimumab treatment in psoriasis with concomitant methotrexate (OPTIMAP): study protocol for a pragmatic, single-blinded, investigator-initiated randomized controlled trial. <i>Trials</i> , 2017, 18, 52.	0.7	15
98	Doing Good Research Is Difficult, Doing No Research Is More Difficult. <i>Journal of Investigative Dermatology</i> , 2017, 137, 993-995.	0.3	0
99	Pregnancy and fetal outcomes after paternal exposure to azathioprine, methotrexate or mycophenolic acid: a critically appraised topic. <i>British Journal of Dermatology</i> , 2017, 176, 866-877.	1.4	14
100	The International TREatment of ATopic Eczema (TREAT) Registry Taskforce: An Initiative to Harmonize Data Collection across National Atopic Eczema Photo- and Systemic Therapy Registries. <i>Journal of Investigative Dermatology</i> , 2017, 137, 2014-2016.	0.3	25
101	One-stop shop with confocal microscopy imaging vs. standard care for surgical treatment of basal cell carcinoma: an open-label, noninferiority, randomized controlled multicentre trial. <i>British Journal of Dermatology</i> , 2017, 177, 735-741.	1.4	25
102	Prevalence of alexithymia in patients with psoriasis and its association with disease burden: a multicentre observational study. <i>British Journal of Dermatology</i> , 2017, 176, 1195-1203.	1.4	37
103	How to write a Critically Appraised Topic: evidence to underpin routine clinical practice. <i>British Journal of Dermatology</i> , 2017, 177, 1007-1013.	1.4	18
104	Methods report: European S3 Guideline on the systemic treatment of psoriasis vulgaris " Update Apremilast and Secukinumab " <sc>EDF</sc> in cooperation with <sc>EADV</sc> and <sc>IPC</sc>. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1964-1977.	1.3	6
105	European S3 Guideline on the systemic treatment of psoriasis vulgaris " Update Apremilast and Secukinumab " <sc>EDF</sc> in cooperation with <sc>EADV</sc> and <sc>IPC</sc>. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1951-1963.	1.3	116
106	When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 623-633.	0.6	170
107	Discrepancy between the clinical and histopathologic diagnosis of soft tissue vascular malformations. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 920-929.e1.	0.6	9
108	DOMINO, doxycycline 40mg vs. minocycline 100mg in the treatment of rosacea: a randomized, single-blinded, noninferiority trial, comparing efficacy and safety. <i>British Journal of Dermatology</i> , 2017, 176, 1465-1474.	1.4	53

#	ARTICLE	IF	CITATIONS
109	Increasing Comorbidities Suggest that Atopic Dermatitis is a Systemic Disorder. <i>Journal of Investigative Dermatology</i> , 2017, 137, 18-25.	0.3	283
110	A prospective randomized controlled trial comparing infliximab and etanercept in patients with moderate-to-severe chronic plaque-type psoriasis: the Psoriasis Infliximab vs. Etanercept Comparison Evaluation (PIECE) study. <i>British Journal of Dermatology</i> , 2017, 176, 624-633.	1.4	40
111	Patients with atopic dermatitis with filaggrin loss-of-function mutations show good but lower responses to immunosuppressive treatment. <i>British Journal of Dermatology</i> , 2017, 177, 1745-1746.	1.4	11
112	Factors Associated with Receiving Biologics or Classic Systemic Therapy for Moderate-to-Severe Psoriasis: Evidence from the PSONET Registries. <i>Acta Dermato-Venereologica</i> , 2017, 97, 516-518.	0.6	2
113	Reporting of symptoms in randomized controlled trials of atopic eczema treatments: a systematic review. <i>British Journal of Dermatology</i> , 2016, 175, 678-686.	1.4	34
114	Methotrexate Dosing Regimen for Plaque-type Psoriasis: A Systematic Review of the Use of Test-dose, Start-dose, Dosing Scheme, Dose Adjustments, Maximum Dose and Folic Acid Supplementation. <i>Acta Dermato-Venereologica</i> , 2016, 96, 23-28.	0.6	39
115	Melanoma-associated leukoderma and vitiligo cannot be differentiated based on blinded assessment by experts in the field. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 1198-1204.	0.6	22
116	Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative). <i>British Journal of Dermatology</i> , 2016, 175, 69-79.	1.4	115
117	Intralesional Bleomycin Injections for Vascular Malformations. <i>Plastic and Reconstructive Surgery</i> , 2016, 137, 244-256.	0.7	97
118	Global Allergy Forum and 3rd Davos Declaration 2015. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2016, 71, 588-592.	2.7	47
119	Effects of systemic immunosuppressive therapies for moderate-to-severe eczema in children and adults. <i>The Cochrane Library</i> , 2015, , .	1.5	4
120	Diphenylcyclopropenone in patients with alopecia areata. A critically appraised topic. <i>British Journal of Dermatology</i> , 2015, 173, 896-909.	1.4	15
121	The efficacy of a health-related quality-of-life intervention during 48 weeks of biologic treatment of patients with moderate to severe psoriasis: results of a multicentre randomized controlled trial. <i>British Journal of Dermatology</i> , 2015, 173, 1091-1094.	1.4	6
122	Clearing up misunderstandings around core outcomes for atopic dermatitis. <i>British Journal of Dermatology</i> , 2015, 173, 623-624.	1.4	3
123	Prioritizing dermatoses: rationally selecting guideline topics. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 1636-1640.	1.3	4
124	<i>in vivo</i> confocal microscopy of basal cell carcinoma: a systematic review of diagnostic accuracy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 1890-1897.	1.3	55
125	European S3 Guidelines on the systemic treatment of psoriasis vulgaris – Update 2015 – Short version – in cooperation with EADV and IPC. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 2277-2294.	1.3	353
126	Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2015, 33, 773-781.	0.8	501

#	ARTICLE	IF	CITATIONS
127	Health-related Quality of Life in Patients with Cutaneous Rosacea: A Systematic Review. <i>Acta Dermato-Venereologica</i> , 2015, 95, 395-400.	0.6	52
128	The correlation of clinical efficacy, serum trough levels and antidrug antibodies in ustekinumab-treated patients with psoriasis in a clinical-practice setting. <i>British Journal of Dermatology</i> , 2015, 173, 855-857.	1.4	35
129	Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial: a critical appraisal. <i>British Journal of Dermatology</i> , 2015, 172, 8-10.	1.4	12
130	Ten years experience with oral immunosuppressive treatment in adult patients with atopic dermatitis in two academic centres. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 1905-1912.	1.3	37
131	Developing a Therapeutic Range of Adalimumab Serum Concentrations in Management of Psoriasis. <i>JAMA Dermatology</i> , 2015, 151, 616.	2.0	75
132	A national study on adherence to a basal cell carcinoma guideline; development of a tool to assess guideline adherence. <i>British Journal of Dermatology</i> , 2015, 172, 1008-1013.	1.4	8
133	An increased risk of non-melanoma skin cancer during <sc>TNF</sc>-inhibitor treatment in psoriasis patients compared to rheumatoid arthritis patients probably relates to disease-related factors. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 752-760.	1.3	51
134	The Harmonizing Outcome Measures for Eczema (HOME) Roadmap: A Methodological Framework to Develop Core Sets of Outcome Measurements in Dermatology. <i>Journal of Investigative Dermatology</i> , 2015, 135, 24-30.	0.3	184
135	Treatment of Basal Cell Carcinoma Using a One-Stop-Shop With Reflectance Confocal Microscopy: Study Design and Protocol of a Randomized Controlled Multicenter Trial. <i>JMIR Research Protocols</i> , 2015, 4, e109.	0.5	11
136	Critically Appraised Topics in the <i>British Journal of Dermatology</i> : response from Jonathan Batchelor and Phyllis Spuls, section editors for <i>BJD</i> 's "Putting Papers into Practice"™. <i>British Journal of Dermatology</i> , 2014, 171, 910-911.	1.4	0
137	Prospective registration of clinical trials published in the <i>British Journal of Dermatology</i> . <i>British Journal of Dermatology</i> , 2014, 171, 681-683.	1.4	7
138	Evaluation of a Tertiary Teledermatology Service Between Peripheral and Academic Dermatologists in The Netherlands. <i>Telemedicine Journal and E-Health</i> , 2014, 20, 332-337.	1.6	11
139	Extent and Consequences of Antibody Formation Against Adalimumab in Patients With Psoriasis. <i>JAMA Dermatology</i> , 2014, 150, 130.	2.0	76
140	Combined Use of Systemic Agents for Psoriasis. <i>JAMA Dermatology</i> , 2014, 150, 1213.	2.0	34
141	Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME). <i>British Journal of Dermatology</i> , 2014, 171, 1318-1325.	1.4	95
142	Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: A systematic review. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 429-438.	1.5	277
143	Drug survival is not significantly different between biologics in patients with psoriasis vulgaris: a single-centre database analysis. <i>British Journal of Dermatology</i> , 2014, 171, 875-883.	1.4	62
144	Composition of Innate Lymphoid Cell Subsets in the Human Skin: Enrichment of NCR + ILC3 in Lesional Skin and Blood of Psoriasis Patients. <i>Journal of Investigative Dermatology</i> , 2014, 134, 2351-2360.	0.3	280

#	ARTICLE	IF	CITATIONS
145	The IL-17A-Producing CD8 + T-Cell Population in Psoriatic Lesional Skin Comprises Mucosa-Associated Invariant T Cells and Conventional T Cells. <i>Journal of Investigative Dermatology</i> , 2014, 134, 2898-2907.	0.3	133
146	The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 134, 800-807.	1.5	257
147	Summary of the Dutch S3-Guidelines on the treatment of psoriasis 2011. <i>Dermatology Online Journal</i> , 2014, 20, .	0.2	33
148	Interventions for nail psoriasis. <i>The Cochrane Library</i> , 2013, , CD007633.	1.5	38
149	Comment on "Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study". <i>British Journal of Dermatology</i> , 2013, 169, 1170-1170.	1.4	0
150	Systemic psoriasis therapy shows high between-country variation: a sign of unwarranted variation? Cross-sectional analysis of baseline data from the PSONET registries. <i>British Journal of Dermatology</i> , 2013, 169, 710-714.	1.4	19
151	Accuracy and reliability of teledermatology with images taken by general practitioners during everyday practice. <i>Journal of Telemedicine and Telecare</i> , 2013, 19, 320-325.	1.4	43
152	Assessment of clinical signs of atopic dermatitis: A systematic review and recommendation. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 132, 1337-1347.	1.5	235
153	The European treatment of severe atopic eczema in children taskforce (TREAT) survey. <i>British Journal of Dermatology</i> , 2013, 169, 901-909.	1.4	94
154	House dust mite reduction in the management of atopic dermatitis. A critically appraised topic. <i>British Journal of Dermatology</i> , 2013, 168, 688-691.	1.4	19
155	Challenges for Synthesising Data in a Network of Registries for Systemic Psoriasis Therapies. <i>Dermatology</i> , 2012, 224, 236-243.	0.9	43
156	Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal. <i>British Journal of Dermatology</i> , 2012, 167, 710-713.	1.4	41
157	Towards global consensus on outcome measures for atopic eczema research: results of the <sc>HOME II</sc> meeting. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2012, 67, 1111-1117.	2.7	169
158	Health-Related Quality-of-Life Assessment in Dermatologic Practice: Relevance and Application. <i>Dermatologic Clinics</i> , 2012, 30, 323-332.	1.0	22
159	Response to a randomized trial of methotrexate vs. azathioprine for severe atopic eczema: a critical appraisal. <i>British Journal of Dermatology</i> , 2012, 166, 704-704.	1.4	4
160	The prevalence of thyroid disease in patients with vitiligo: a systematic review. <i>British Journal of Dermatology</i> , 2012, 167, 1224-1235.	1.4	83
161	Measurement Properties of Outcome Measures for Vitiligo. <i>Archives of Dermatology</i> , 2012, 148, 1302.	1.7	40
162	The efficacy of a health-related quality-of-life intervention during 48 weeks of biologic treatment of patients with moderate to severe psoriasis: study protocol for a multicenter randomized controlled trial. <i>Trials</i> , 2012, 13, 236.	0.7	4

#	ARTICLE	IF	CITATIONS
163	A randomized trial of methotrexate versus azathioprine for severe atopic eczema. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 128, 353-359.	1.5	231
164	Validation and refinement of the Millennium Criteria for atopic dermatitis. <i>Journal of Dermatology</i> , 2011, 38, no-no.	0.6	14
165	Survival in cancer patients hospitalized for psoriasis: a commentary. <i>British Journal of Dermatology</i> , 2011, 165, 1-2.	1.4	1
166	Laser and intense pulsed light therapy for the treatment of hypertrophic scars: a systematic review. <i>British Journal of Dermatology</i> , 2011, 165, 934-942.	1.4	112
167	Teledermatology applied following patient selection by general practitioners in daily practice improves efficiency and quality of care at lower cost. <i>British Journal of Dermatology</i> , 2011, 165, 1058-1065.	1.4	130
168	Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men. <i>JDDG - Journal of the German Society of Dermatology</i> , 2011, 9, S1-57.	0.4	215
169	Definition of treatment goals for moderate to severe psoriasis: a European consensus. <i>Archives of Dermatological Research</i> , 2011, 303, 1-10.	1.1	690
170	Prospective comparison of three guideline development methods for treatment of actinic keratosis. <i>BMJ Quality and Safety</i> , 2011, 20, 832-841.	1.8	6
171	Etanercept. <i>Archives of Dermatology</i> , 2011, 147, 79.	1.7	16
172	Off-label Use of Azathioprine in Dermatology. <i>Archives of Dermatology</i> , 2011, 147, 474.	1.7	79
173	Is there a rural/urban gradient in the prevalence of eczema? A systematic review. <i>British Journal of Dermatology</i> , 2010, 162, 964-973.	1.4	95
174	On the development of the European S3 guidelines on the systemic treatment of psoriasis vulgaris: structure and challenges. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 1458-1467.	1.3	33
175	Atopic eczema or atopiform dermatitis. <i>Experimental Dermatology</i> , 2010, 19, 325-331.	1.4	53
176	Excimer laser vs. clobetasol propionate 0.05% ointment in prurigo form of atopic dermatitis: a randomized controlled trial, a pilot. <i>British Journal of Dermatology</i> , 2010, 163, 823-831.	1.4	46
177	Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept. <i>British Journal of Dermatology</i> , 2010, 163, 838-846.	1.4	45
178	How Good Are Clinical Severity and Outcome Measures for Psoriasis?: Quantitative Evaluation in a Systematic Review. <i>Journal of Investigative Dermatology</i> , 2010, 130, 933-943.	0.3	199
179	Tertiary Teledermatology: A Systematic Review. <i>Telemedicine Journal and E-Health</i> , 2010, 16, 56-62.	1.6	40
180	Off-label use of efalizumab in dermatology. <i>Expert Review of Dermatology</i> , 2010, 5, 535-547.	0.3	6

#	ARTICLE	IF	CITATIONS
181	A pilot study on tertiary teledermatology: feasibility and acceptance of telecommunication among dermatologists. <i>Journal of Telemedicine and Telecare</i> , 2010, 16, 447-453.	1.4	16
182	Extent and Clinical Consequences of Antibody Formation Against Adalimumab in Patients With Plaque Psoriasis. <i>Archives of Dermatology</i> , 2010, 146, 127-32.	1.7	137
183	Evaluation of and Perspectives on Guidelines: What Is Important?. <i>Journal of Investigative Dermatology</i> , 2010, 130, 2348-2349.	0.3	5
184	The Misperception That Clinical Trial Data Reflect Long-term Drug Safety. <i>Archives of Dermatology</i> , 2009, 145, 1037-9.	1.7	15
185	National Registries of Systemic Treatment for Psoriasis and the European "Psonet"™ Initiative. <i>Dermatology</i> , 2009, 218, 347-356.	0.9	50
186	Patient preferences and satisfaction with systemic therapies for psoriasis: an area to be explored. <i>British Journal of Dermatology</i> , 2009, 160, 1340-1343.	1.4	24
187	Experience with biologics for psoriasis in daily practice: switching is worth a try. <i>British Journal of Dermatology</i> , 2009, 161, 948-951.	1.4	34
188	European S3 Guidelines on the systemic treatment of psoriasis vulgaris. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009, 23, 1-70.	1.3	683
189	The burden of vitiligo: Patient characteristics associated with quality of life. <i>Journal of the American Academy of Dermatology</i> , 2009, 61, 411-420.	0.6	145
190	Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial. <i>British Journal of Dermatology</i> , 2008, 145, 438-445.	1.4	5
191	Diagnostic criteria for atopic dermatitis: a systematic review. <i>British Journal of Dermatology</i> , 2008, 158, 754-765.	1.4	212
192	Knowledge, attitudes and use of the guidelines for the treatment of moderate to severe plaque psoriasis among Dutch dermatologists. <i>British Journal of Dermatology</i> , 2008, 159, ???-???	1.4	21
193	Clinical differences between atopic and atopiform dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2008, 58, 407-414.	0.6	99
194	Topical treatments in psoriasis: today and tomorrow. <i>Clinics in Dermatology</i> , 2008, 26, 432-437.	0.8	30
195	Initial experience with routine administration of etanercept in psoriasis. <i>British Journal of Dermatology</i> , 2006, 155, 808-814.	1.4	41
196	The Course of Chronic Plaque-Type Psoriasis in Placebo Groups of Randomized Controlled Studies. <i>Archives of Dermatology</i> , 2004, 140, 338-44; discussion 344.	1.7	16
197	Methotrexate versus Cyclosporine in Moderate-to-Severe Chronic Plaque Psoriasis. <i>New England Journal of Medicine</i> , 2003, 349, 658-665.	13.9	446
198	The Development of Practice Guidelines for the Treatment of Severe Plaque Form Psoriasis. <i>Archives of Dermatology</i> , 1998, 134, 1591-6.	1.7	33

#	ARTICLE	IF	CITATIONS
199	Effectiveness of the Ascomycin Macrolactam SDZ ASM 981 in the Topical Treatment of Atopic Dermatitis. Archives of Dermatology, 1998, 134, 805-9.	1.7	194
200	A systematic review of five systemic treatments for severe psoriasis. British Journal of Dermatology, 1997, 137, 943-949.	1.4	56
201	A systematic review of five systemic treatments for severe psoriasis. British Journal of Dermatology, 1997, 137, 943-949.	1.4	63
202	A systematic review of five systemic treatments for severe psoriasis. British Journal of Dermatology, 1997, 137, 943-9.	1.4	12
203	Phototherapy for atopic eczema. The Cochrane Library, 0, , .	1.5	4
204	Effects of systemic immunosuppressive therapies for moderate-to-severe eczema in children and adults. The Cochrane Library, 0, , .	1.5	0